中國奧園(03883.HK)附屬以10.2億元成功競得奧園美谷旗下公司股權
格隆匯7月14日丨中國奧園(03883.HK)發佈公吿,奧園美谷(公司間接非全資附屬公司)擬根據中國有關規則及法規,通過在北交所進行公開招標程序轉讓其所持有的京漢置業100%股權、北京養嘉100%股權及蓬萊華錄35%股權。透過公開招標進行的目標附屬公司股權潛在轉讓的基準價格為人民幣10.2億元。
公開招標於2021年7月13日已經完成。於2021年7月14日,公司間接全資附屬公司深圳凱弦獲北交所通知,其以總代價人民幣10.2億元成功競得目標附屬公司股權。有關奧園美谷向深圳凱弦轉讓目標附屬公司股權的正式股權轉讓協議已於同日籤立。股權轉讓協議的完成須待奧園美谷的股東批准及相關監管部門的批准方可作實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.